Marimastat treatment significantly reduced proinflammatory cytokines (Il‐1β and Il‐6), ER stress markers (CHOP and Grp78), and tumor markers (CD31 and AFP) (Fig. 7A). This evidence concerns the gene DDIT3 and neoplasm.